Yifan Xinfu Pharmaceutical Co Ltd - Asset Resilience Ratio
Yifan Xinfu Pharmaceutical Co Ltd (002019) has an Asset Resilience Ratio of 0.53% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Yifan Xinfu Pharmaceutical Co Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2023)
This chart shows how Yifan Xinfu Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Yifan Xinfu Pharmaceutical Co Ltd assets under control.
Liquid Assets Composition Over Time
This chart breaks down Yifan Xinfu Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Yifan Xinfu Pharmaceutical Co Ltd (002019) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥65.00 Million | 0.53% |
| Total Liquid Assets | CN¥65.00 Million | 0.53% |
Asset Resilience Insights
- Limited Liquidity: Yifan Xinfu Pharmaceutical Co Ltd maintains only 0.53% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Yifan Xinfu Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Yifan Xinfu Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.33% |
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
AstraZeneca PLC
MX:AZNN |
Drug Manufacturers - General | 0.03% |
|
Novartis AG ADR
NYSE:NVS |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SHE:300357 |
Drug Manufacturers - General | 9.91% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
Annual Asset Resilience Ratio for Yifan Xinfu Pharmaceutical Co Ltd (2015–2023)
The table below shows the annual Asset Resilience Ratio data for Yifan Xinfu Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.65% | CN¥75.01 Million ≈ $10.98 Million |
CN¥11.50 Billion ≈ $1.68 Billion |
-0.11pp |
| 2022-12-31 | 0.76% | CN¥95.50 Million ≈ $13.97 Million |
CN¥12.54 Billion ≈ $1.84 Billion |
-2.86pp |
| 2021-12-31 | 3.62% | CN¥440.39 Million ≈ $64.44 Million |
CN¥12.17 Billion ≈ $1.78 Billion |
+3.22pp |
| 2020-12-31 | 0.40% | CN¥46.73 Million ≈ $6.84 Million |
CN¥11.71 Billion ≈ $1.71 Billion |
+0.05pp |
| 2019-12-31 | 0.35% | CN¥39.00 Million ≈ $5.71 Million |
CN¥11.07 Billion ≈ $1.62 Billion |
-1.03pp |
| 2018-12-31 | 1.39% | CN¥135.58 Million ≈ $19.84 Million |
CN¥9.77 Billion ≈ $1.43 Billion |
-6.37pp |
| 2017-12-31 | 7.76% | CN¥680.00 Million ≈ $99.51 Million |
CN¥8.77 Billion ≈ $1.28 Billion |
+4.93pp |
| 2016-12-31 | 2.83% | CN¥197.50 Million ≈ $28.90 Million |
CN¥6.98 Billion ≈ $1.02 Billion |
+1.79pp |
| 2015-12-31 | 1.03% | CN¥47.00 Million ≈ $6.88 Million |
CN¥4.55 Billion ≈ $665.33 Million |
-- |
About Yifan Xinfu Pharmaceutical Co Ltd
Yifan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products, vitamins, and polymer materials in China, South Korea, the Philippines, Vietnam, Italy, Thailand, and internationally. It offers pharmaceutical products, such as biopharmaceuticals, chemical drugs, and traditional Chinese medicines; vitamin products, including vitamin B5 and provi… Read more